Discovery of chromen-2-one based hybrid molecules as potential anti-tubercular agents and their docking for MTB

Tuberculosis (TB) remains a critical global health challenge, as identified by the World Health Organization (WHO), which names it the world’s leading infectious killer. Caused by Mycobacterium tuberculosis, TB primarily affects the lungs, leading to symptoms such as chronic cough, weight loss, and fatigue, though it can also impact other organs, including the brain, kidneys, and spine. Transmission occurs when individuals inhale droplets containing the bacteria, allowing it to reach the alveoli after passing through the respiratory tract. Currently, the FDA-approved medications for TB treatment include rifampin, isoniazid, pyrazinamide, and ethambutol. This study aims to develop a naturally occurring compound through synthetic chemistry, targeting TB with modifications at side chains to achieve lower IC50 values compared to existing drugs. For the Synthesized of substituted amide Derivatives (3a - 3j) to achieve this, a library of amides was synthesized and coupled with a chromen molecule is Compound 4a - 4 j. the final synthesized compound was subjected to pharmacokinetic studies and molecular docking to evaluate its efficacy.